12.56
0.42 (3.50%)
| Previous Close | 12.13 |
| Open | 12.23 |
| Volume | 68,452 |
| Avg. Volume (3M) | 171,516 |
| Market Cap | 549,873,856 |
| Price / Earnings (TTM) | 179.36 |
| Price / Sales | 3.17 |
| Price / Book | 1.82 |
| 52 Weeks Range | |
| Earnings Date | 14 May 2025 |
| Profit Margin | 31.01% |
| Operating Margin (TTM) | 29.97% |
| Diluted EPS (TTM) | 0.070 |
| Total Debt/Equity (MRQ) | 8.84% |
| Current Ratio (MRQ) | 16.10 |
| Operating Cash Flow (TTM) | 69.88 M |
| Levered Free Cash Flow (TTM) | 52.09 M |
| Return on Assets (TTM) | 23.07% |
| Return on Equity (TTM) | 34.38% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Maze Therapeutics, Inc. | Bearish | - |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.5 |
| Average | -0.25 |
|
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 5.91% |
| % Held by Institutions | 92.17% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Trv Gp Iv, Llc | 31 Mar 2025 | 6,073,958 |
| Frazier Life Sciences Management, L.P. | 31 Mar 2025 | 4,129,001 |
| Arch Venture Management, Llc | 31 Mar 2025 | 4,120,053 |
| Deep Track Capital, Lp | 31 Mar 2025 | 3,269,126 |
| Matrix Capital Management Company, Lp | 31 Mar 2025 | 2,486,184 |
| Foresite Capital Management Iv, Llc | 31 Mar 2025 | 2,111,919 |
| Ah Capital Management, L.L.C. | 31 Mar 2025 | 1,702,225 |
| Janus Henderson Group Plc | 31 Mar 2025 | 1,246,370 |
| General Catalyst Group Management, Llc | 31 Mar 2025 | 1,035,910 |
| Trv Gp V, Llc | 31 Mar 2025 | 950,800 |
| Casdin Capital, Llc | 31 Mar 2025 | 946,357 |
| Logos Global Management Lp | 31 Mar 2025 | 936,914 |
| Woodline Partners Lp | 31 Mar 2025 | 929,102 |
| 52 Weeks Range | ||
| Median | 19.00 (51.33%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Guggenheim | 02 Apr 2025 | 19.00 (51.33%) | Buy | 10.37 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 29 May 2025 | Announcement | Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference |
| 14 May 2025 | Announcement | Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones |
| 13 May 2025 | Announcement | Maze Therapeutics to Participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference |
| 31 Mar 2025 | Announcement | Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |